UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036325
Receipt number R000040684
Scientific Title Effects of a Test Food for Defecation Improvement.
Date of disclosure of the study information 2019/03/28
Last modified on 2019/09/17 17:31:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of a Test Food for Defecation Improvement.

Acronym

Effects of a Test Food for Defecation Improvement.

Scientific Title

Effects of a Test Food for Defecation Improvement.

Scientific Title:Acronym

Effects of a Test Food for Defecation Improvement.

Region

Japan


Condition

Condition

N/A(healthy adults)

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to evaluate effects of a test food for defecation improvement and its safety(a randomized, double-blind, placebo-controlled, parallel-group study).

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

[1]Indexes for evaluating defecation (The Japanese Version of the Constipation Assessment Scale (1), Patient Assessment of Constipation of Quality Of Life scale (1), Bristol stool scale (1), bowel diary (2)).
(1):Screening, Week 0, Week 2, Week 4.
(2):From the first day of ingestion of a test material to the last day of the test.

Key secondary outcomes

*Safety
[1]Blood pressure, pulsation (Screening, Week 0, Week 4).
[2]Weight, body fat percentage, BMI (Screening, Week 0, Week 4).
[3]Doctor's questions (Screening, Week 0, Week 4).
[4]Subject's diary (each day during the test period).


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Oral intake of the test product (4 capsules in a day for 4 weeks)

Interventions/Control_2

Oral intake of the placebo product (4 capsules in a day for 4 weeks)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >

Gender

Male and Female

Key inclusion criteria

[1]Healthy Japanese males and females aged 20-59 years.
[2]Individuals who are healthy and have no chronic physical disease.
[3]Individuals with a tendency for constipation (at 3-5 times of defecation per week); whose stool shape is relatively hard and who have unpleasant sensation on defecation.
[4]Individuals whose written informed consent has been obtained.
[5]Individuals who can have an examination on a designated check day.
[6]Individuals judged appropriate for the study by the principal.

Key exclusion criteria

[1]Individuals using medical products.
[2]Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia.
[3]Individuals whose stool frequency is less than 3 times per week.
[4]Individuals who are constipated because of intaking internal medicine.
[5]Individuals who have idiopathic constipation.
[6]Individuals whose eating habits are irregular.
[7]Individuals who used a drug to treat a disease in the past 1 month (except temporal usage for pollenosis).
[8]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease.
[9]Individuals who are a patient or have a history of or endocrine disease.
[10]Individuals whose BMI is over 30.
[11]Individuals who are sensitive to a test product or other foods, and medical products.
[12]Individuals who intake laxatives, antiflatulent etc. aiming to improve bowel movements.
[13]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day).
[14]Individuals with possible changes of life style, such as working a night shift, during the test period.
[15]Individuals who are or are possibly, or are lactating.
[16]Individuals who participated in other clinical studies in the past 3 months.
[17]Individuals who are or whose family is engaged in functional foods or cosmetics.
[18]Individuals judged inappropriate for the study by the principal.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Toshifumi
Middle name
Last name Okusa

Organization

Oriental Ueno Detection Center, General Incorporated Association Oriental Occupational Health Association Tokyo Branch

Division name

Head of Center

Zip code

110-0005

Address

1-20-11 Ueno Taito-ku Tokyo 110-0005, JAPAN

TEL

+81-3-5816-0711

Email

info@tes-h.co.jp


Public contact

Name of contact person

1st name Ryoma
Middle name
Last name Shimizu

Organization

TES Holdings Co., Ltd.

Division name

Administrative Department of Clinical Trials

Zip code

110-0015

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

TEL

+81-3-601-8480

Homepage URL


Email

r.shimizu@tes-h.co.jp


Sponsor or person

Institute

TES Holdings Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Kobayashi Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ueno-Asagao Clinic Ethical Review Committee

Address

6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN

Tel

+81-3-6240-1162

Email

i.takahashi@tes-h.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 03 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

60

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 01 Month 29 Day

Date of IRB

2019 Year 01 Month 16 Day

Anticipated trial start date

2019 Year 03 Month 04 Day

Last follow-up date

2019 Year 04 Month 07 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 03 Month 28 Day

Last modified on

2019 Year 09 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040684


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name